ModiQuest Research BV, the Dutch antibody generation services company, today announced that it has expanded its research collaboration with Dako – an Agilent Technologies company.
After the successful generation of monoclonal antibodies by ModiQuest against a proprietary target selected by Dako earlier this year, both parties have extended their collaboration with three additional targets for monoclonal antibody generation by ModiQuest. During the collaboration, ModiQuest will make use of its proprietary hybridoma-electrofusion technology (ModiFuseTM)....
ModiQuest Research BV, the Dutch antibody generation services company, today announced that it has entered into a research collaboration with the Beckman Research Institute of the City of Hope (“BRICOH”) aimed at the generation of novel monoclonal antibodies against a target selected by and proprietary to BRICOH.
During the collaboration, ModiQuest will make use of its proprietary B-cell selection technology, ModiSelectTM. Financials details of the collaboration were not disclosed. “We are delighted that the Beckman Research Institute of the City of Hope has selected ModiQuest Research as an antibody generation collaborator,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration again demonstrates the value of our broad and unique technology platform for finding monoclonal antibodies against some of the most difficult antigen targets.”...
ModiQuest Research Delivers Novel Therapeutic Antibodies For Rheumatoid Arthritis
Nov 30, 2011ModiQuest Research, the full service provider for antibody generation, engineering and optimization, has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models...
Technologies For Developing New Antibody Treatments Showcasing At Human Antibodies and Hybridomas (HAH) 2011
Oct 25, 2011Combining accurate, early diagnostic tests for autoimmune disease, and new antibody treatment options are two themes being presented by antibody technology experts, ModiQuest Research at HAH 2011 (7-9 November 2011, Cannes, France). ModiQuest Research's technology includes monoclonal antibody generation and specialist immunological reagents to support the research and development of new antibody therapies and diagnostics. President and CEO, Dr Jos Raats will present latest data on new antibodies and early diagnostics for rheumatoid arthritis, using their hybridoma and phage display platforms...
The Technology Behind The New Monoclonal Antibody Drugs: Meet ModiQuest Research At Biotechnica 2011
Oct 7, 2011Rapid growth in the monoclonal antibodies market has been made possible by technological advances in recombinant monoclonal technologies, showcased by antibody technology experts, ModiQuest Research, at BIOTECHNICA 2011 (11-13 October, Hannover, Germany). ModiQuest CEO and President, Dr Jos Raats will be on hand to discuss how their technologies and specialist reagents have enabled research and development of new antibody treatments, plus diagnostics, across a range of therapy areas including autoimmune disease and cancer...
ModiQuest Research Makes Antibody R&D Easier With Their New Website
Oct 5, 2011ModiQuest Research, the antibody technology experts, announce the launch of their new website. With a fresh new look, it will save time and effort for antibody research teams worldwide. An intuitive structure, ‘quick quotes' and fixed pricing look set to make www.modiquestresearch.com the go-to resource for the routine purchase of a wide range of antibody products and services...
ModiQuest Research and BINDER: successful together
Sep 10, 2010ModiQuest Research is a young and dynamic biotechnology company that is based in Nijmegen, the Netherlands. ModiQuest Research discovers, develops, and markets new tools and technologies for use in human diagnostics and therapeutics.
ModiQuest Research, the full service provider for antibody generation, engineering and optimization, has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models...
Combining accurate, early diagnostic tests for autoimmune disease, and new antibody treatment options are two themes being presented by antibody technology experts, ModiQuest Research at HAH 2011 (7-9 November 2011, Cannes, France). ModiQuest Research's technology includes monoclonal antibody generation and specialist immunological reagents to support the research and development of new antibody therapies and diagnostics. President and CEO, Dr Jos Raats will present latest data on new antibodies and early diagnostics for rheumatoid arthritis, using their hybridoma and phage display platforms...
Rapid growth in the monoclonal antibodies market has been made possible by technological advances in recombinant monoclonal technologies, showcased by antibody technology experts, ModiQuest Research, at BIOTECHNICA 2011 (11-13 October, Hannover, Germany). ModiQuest CEO and President, Dr Jos Raats will be on hand to discuss how their technologies and specialist reagents have enabled research and development of new antibody treatments, plus diagnostics, across a range of therapy areas including autoimmune disease and cancer...